Tarsus Pharmaceuticals reshuffles board, appoints new committee chair
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a $1.78 billion market cap company specializing in biological products, announced ...
Business Wire2d
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Arrowhead says FDA accepts NDA for investigational plozasiran
Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...
San Francisco Examiner5d
Triplebar Bio Strengthens Advisory Board with the Addition of Renowned Experts
Triplebar, a pioneering biotechnology company based in Emeryville which is focused on developing cost effective and effective ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Oregon Business5d
Optimizing the Value of a GP Advisory Board for Private Equity Funds
Launching a private equity fund is an exciting yet daunting endeavor; and a General Partner (GP) Advisory Board can be a ...
manilatimes7d
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Mr. Pasternak brings decades of global pharmaceutical leadership experience ...
KOMU10d
MU Health Care offers support program for Missouri health care professionals
MU Health Care's Physician and Health Professional Wellness Program offers support services to health care professionals ...
RP launches talent scheme backed by biopharma firms to better prepare students for jobs
This will put students in good stead to take up skilled roles in biopharma manufacturing. Read more at straitstimes.com.
TMCnet13d
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
Prior to joining Bright Minds, Dr. Collins simultaneously served as CEO of Biscayne Neurotherapeutics, a small molecule clinical stage company focused on CNS disorders, and CEO and President of ...